Skip Nav Destination
Drug Discovery
Anti-fibrotic Drug Discovery
Edited by
Malliga R Iyer
Malliga R Iyer
National Institutes of Health, MD, USA
Search for other works by this author on:
Hardback ISBN:
978-1-78801-510-3
PDF ISBN:
978-1-78801-578-3
EPUB ISBN:
978-1-83916-051-6
Special Collection:
2020 ebook collection
Series:
Drug Discovery
No. of Pages:
340
Published online:
17 Feb 2020
Published in print:
03 Mar 2020
About this book
Fibrosis is a condition with globally high unmet medical need, and as such is a highly active area of academic and pharmaceutical research covering multiple treatment targets, organs, tissues and therapeutic approaches. Anti-fibrotic Drug Discovery is a single source reference for the latest drug-discovery approaches to tackle fibrosis in various tissues, comprehensively covering recent success and future perspectives on emerging therapeutic intervention points. The book highlights significant pre-clinical and clinical drugs currently being developed globally for this disorder. This book is ideal for postgraduate students and researchers with an interest in anti-fibrotic drug discovery as well as clinicians specialising in liver, kidney, heart and lung disease, in which fibrosis plays a key role in pathology.
Anti-fibrotic Drug Discovery, The Royal Society of Chemistry, 2020.
Download citation file:
Digital access
$250.00
Print format
Anti-fibrotic Drug Discovery
$235.00
Table of contents
-
CHAPTER 1: TGFβ Signalingp1-36ByAnne-Ulrike TrendelenburgAnne-Ulrike TrendelenburgNovartis Institutes for Biomedical ResearchMusculoskeletal Disease AreaCambridgeMA 02139USA[email protected]Search for other works by this author on:
-
CHAPTER 2: Targeting the αv Integrins in Fibroproliferative Diseasep37-75ByC. B. Nanthakumar;C. B. NanthakumarFibrosis Discovery Performance Unit, Respiratory Therapy Area, Medicines Research Centre, GlaxoSmithKline R&DGunnels Wood RoadStevenageSG1 2NYUK[email protected]Search for other works by this author on:R. J. D. Hatley;R. J. D. HatleyFibrosis Discovery Performance Unit, Respiratory Therapy Area, Medicines Research Centre, GlaxoSmithKline R&DGunnels Wood RoadStevenageSG1 2NYUK[email protected]Search for other works by this author on:R. J. SlackR. J. SlackFibrosis Discovery Performance Unit, Respiratory Therapy Area, Medicines Research Centre, GlaxoSmithKline R&DGunnels Wood RoadStevenageSG1 2NYUK[email protected]Search for other works by this author on:
-
CHAPTER 3: Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor Activatorsp76-116ByChristina Lamers;Christina LamersUniversity Basel, Molecular PharmacyKlingelberstr. 50CH-4056 BaselSwitzerlandSearch for other works by this author on:Daniel MerkDaniel MerkGoethe University Frankfurt, Institute of Pharmaceutical ChemistryMax-von-Laue-Str. 9D-60438 FrankfurtGermany[email protected]Swiss Federal Institute of Technology (ETH) Zurich, Institute of Pharmaceutical SciencesVladimir-Prelog-Weg 4CH-8093 ZurichSwitzerlandSearch for other works by this author on:
-
CHAPTER 4: Autotaxin Inhibitors in Fibrosisp117-144ByB. HeckmannB. HeckmannSearch for other works by this author on:
-
CHAPTER 5: Inhibition of LOXL2 and Other Lysyl Oxidase (Like) Enzymes: Intervention at the Core of Fibrotic Pathologyp145-164ByDieter HamprechtDieter HamprechtSearch for other works by this author on:
-
CHAPTER 6: Targeting the Ubiquitin Proteasome System in Pulmonary Fibrosisp165-184ByAndrew J. Thorley;Andrew J. ThorleyRespiratory Disease Area, Novartis Institutes for BioMedical Research700 Main StreetCambridgeMassachusetts02139USA[email protected]Search for other works by this author on:Simon Krautwald;Simon KrautwaldGlobal Discovery Chemistry, Novartis Institutes for BioMedical Research22 Windsor StreetCambridgeMassachusetts02139USASearch for other works by this author on:David J. RowlandsDavid J. RowlandsRespiratory Disease Area, Novartis Institutes for BioMedical Research700 Main StreetCambridgeMassachusetts02139USA[email protected]Search for other works by this author on:
-
CHAPTER 7: Galectin-3 Involvement in Fibrotic Diseasesp185-210ByXiaosong Jiang;Xiaosong JiangMolecular Biosciences, School of Veterinary Medicine, University of California at DavisDavisCA95616USASearch for other works by this author on:Natalie J. Torok;Natalie J. TorokDepartment of Medicine, Stanford UniversityStanfordCA 94305USAVeterans Admin Palo Alto Health Care SystemPalo Alto 94304USASearch for other works by this author on:Joseph J. Barchi JrJoseph J. Barchi JrChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute at FrederickFrederickMD 21702USA[email protected]Search for other works by this author on:
-
CHAPTER 8: Emerging Role of CXCR4 in Fibrosisp211-234ByXilun Anthony Wang;Xilun Anthony WangThe Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe UniversityBundooraMelbourne3086Australia[email protected]Search for other works by this author on:Katherine Griffiths;Katherine GriffithsThe Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe UniversityBundooraMelbourne3086Australia[email protected]Search for other works by this author on:Michael FoleyMichael FoleyThe Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe UniversityBundooraMelbourne3086Australia[email protected]AdAlta Limited15/2 Park DriveBundoora3083AustraliaSearch for other works by this author on:
-
CHAPTER 9: BH3 Mimetic Drugs for Anti-fibrotic Therapyp235-258ByDavid LagaresDavid LagaresFibrosis Research Center, Massachusetts General HospitalBostonMAUSACenter for Immunology and Inflammatory Diseases, Massachusetts General HospitalBostonMAUSADivision of Pulmonary and Critical Care, Department of Medicine, Massachusetts General HospitalBostonMAUSASearch for other works by this author on:
-
CHAPTER 10: Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunitiesp259-306ByViviana Cremasco;Viviana CremascoNovartis Institutes for BioMedical Research250 Massachusetts AveCambridgeMA 02139USA[email protected]Search for other works by this author on:Jonathan ChangJonathan ChangNovartis Institutes for BioMedical Research250 Massachusetts AveCambridgeMA 02139USA[email protected]Search for other works by this author on:
-
CHAPTER 11: Targeting Fibroblasts in Fibrosis and Cancerp307-339ByAhmed M. R. H. Mostafa;Ahmed M. R. H. MostafaTargeted Therapeutics, Department of Biomaterials Science and Technology, Technical Medical Centre, University of TwenteEnschedeNetherlands[email protected]Search for other works by this author on:Ruchi Bansal;Ruchi BansalTargeted Therapeutics, Department of Biomaterials Science and Technology, Technical Medical Centre, University of TwenteEnschedeNetherlands[email protected]Search for other works by this author on:Jai PrakashJai PrakashTargeted Therapeutics, Department of Biomaterials Science and Technology, Technical Medical Centre, University of TwenteEnschedeNetherlands[email protected]Search for other works by this author on:
Spotlight
Advertisement
Advertisement
